Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bull 2X Shares

25.28
-0.2684-1.05%
Volume:39.77K
Turnover:1.03M
Market Cap:15.17M
PE:- -
High:26.74
Open:25.98
Low:25.28
Close:25.55
52wk High:34.28
52wk Low:11.50
Shares:600.00K
Float Shares:600.00K
Volume Ratio:0.32
T/O Rate:6.63%
Dividend:3.09
Dividend Rate:12.21%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

'His credit rating is wrecked': My son and his girlfriend mingled their finances. Big mistake.

Dow Jones
·
1 hour ago

Daiwa Securities Adjusts Price Target on Eli Lilly to $1,250 From $1,230, Maintains Buy Rating

MT Newswires Live
·
1 hour ago

BUZZ-Australia's CSL recovers after signing licensing deal with Eli Lilly

Reuters
·
11 hours ago

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
13 hours ago

BRIEF-CSL And Lilly Enter Licensing Agreement For Clazakizumab

Reuters
·
14 hours ago

Eli Lilly Stock (LLY) Rises on Plan to Invest $1 Billion in India

TIPRANKS
·
18 hours ago

Lilly targets India as global export hub amid booming Mounjaro sales, executive says

Reuters
·
Yesterday

Eli Lilly Aims to Establish India as Global Export Hub Amid Mounjaro Sales Surge

Deep News
·
Yesterday

Is Eli Lilly (LLY) Pricing Make Sense After Tripling In Three Years?

Simply Wall St.
·
Yesterday

Big Tech Stocks Lose Billions as AI Spending Fears Hit Valuations

Reuters
·
Yesterday

Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill

TIPRANKS
·
Yesterday

Eli Lilly to Join TD Cowen's 46th Annual Health Care Conference

Reuters
·
Feb 16

Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 16

REFILE-Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Reuters
·
Feb 16

Lilly's Retevmo Delivers Event-Free Survival Benefit As Adjuvant Therapy In Early-Stage Ret Fusion-Positive Lung Cancer

Reuters
·
Feb 16

Eli Lilly reports Phase 3 LIBRETTO-432 study of Retevmo met primary endpoint

TIPRANKS
·
Feb 16

Lilly Reports Positive Phase 3 Results for Selpercatinib in Early-Stage RET Fusion-Positive Lung Cancer

Reuters
·
Feb 16

Eli Lilly - Phase 3 Libretto-432 Study Meets Primary Endpoint With Improved Event-Free Survival

THOMSON REUTERS
·
Feb 16

Lilly's Retevmo (Selpercatinib) Delivers Substantial Event-Free Survival Benefit as an Adjuvant Therapy in Early-Stage Ret Fusion-Positive Lung Cancer

THOMSON REUTERS
·
Feb 16

Eli Lilly - Overall Survival Results Trended in Favor of Selpercatinib, but Were Immature at Time of This Analysis With Few Events Observed

THOMSON REUTERS
·
Feb 16